Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.
Activation of resting T cells induces synthesis of interleukin-2 (IL-2) and expression of its specific high-affinity receptor. We proposed a multichain model for the high-affinity IL-2 receptor in which both a 55-kilodalton IL-2-binding peptide identified by the anti-Tac monoclonal antibody and a 70/75-kilodalton IL-2-binding peptide are associated in a receptor complex. The IL-2 receptor is proving to be an extraordinarily versatile therapeutic target, since it is expressed by the abnormal T cells in patients with certain lymphoid malignancies or autoimmune disorders and in individuals rejecting allografts, whereas it is not expressed by normal resting cells. Monoclonal antibodies and toxin-lymphokine conjugates directed toward IL-2 receptors represent novel therapeutic agents for these clinical conditions.
Waldmann
T A
TA
Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000378:metabolism / Q000628:therapy; D055598:Chemical Phenomena; D002621:Chemistry; D003001:Cloning, Molecular; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000378:metabolism / Q000628:therapy*; D008214:Lymphocytes / Q000032:analysis / Q000502:physiology; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000235:genetics / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2